Biosystems Immunolab

BSI's main clients are industrial partners in the global healthcare market, such as large pharmaceutical and diagnostic companies. These partners either license or purchase BSI's diagnostic candidates to bring them to market faster. BSI's diagnostics are designed to work on widely-used platforms like protein arrays and ELISA, which are common tools in medical labs.

The company makes money by licensing or selling its diagnostic products. They also offer specialized laboratory services using their proprietary monoclonal antibody (mAb) proteomics technology. This technology is particularly advanced because it doesn't just measure the amount of a protein but also looks at the quality and variability of proteins, which can be crucial for early disease detection.

BSI's product pipeline includes diagnostics for lung, breast, and colon cancer, as well as diabetes. For example, their lung cancer diagnostic panel was purchased by Roche Diagnostics in 2012. Early detection is critical for diseases like lung cancer, where the survival rate can significantly improve with timely diagnosis.

In summary, BSI operates in the healthcare diagnostics market, serving large industrial partners by providing advanced diagnostic tests and laboratory services. Their business model focuses on licensing and selling these diagnostic products, leveraging their unique technology to offer more detailed and early disease detection.